
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4948623/publications.pdf Version: 2024-02-01



SHELLA F O'RDIEN

#	Article	IF	CITATIONS
1	Current incidence and estimated residual risk of transfusionâ€transmitted infections in donations made to Canadian Blood Services. Transfusion, 2007, 47, 316-325.	1.6	131
2	Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. Lancet Haematology,the, 2016, 3, e246-e254.	4.6	57
3	The Epidemiology of Imported Malaria and Transfusion Policy in 5 Nonendemic Countries. Transfusion Medicine Reviews, 2015, 29, 162-171.	2.0	53
4	Donor understanding and attitudes about current and potential deferral criteria for highâ€risk sexual behavior. Transfusion, 2011, 51, 1829-1834.	1.6	51
5	Hepatitis�B virus DNA?positive, hepatitis�B surface antigen?negative blood donations intercepted by anti-hepatitis�B core antigen testing: the Canadian Blood Services experience. Transfusion, 2007, 47, 1809-1815.	1.6	49
6	SARSâ€CoVâ€2 seroprevalence among blood donors after the first COVIDâ€19 wave in Canada. Transfusion, 2021, 61, 862-872.	1.6	48
7	Iron deficiency in <scp>C</scp> anadian blood donors. Transfusion, 2014, 54, 775-779.	1.6	47
8	How do I interpret a confidence interval?. Transfusion, 2016, 56, 1680-1683.	1.6	44
9	The Canadian Blood Donor Health Assessment Questionnaire: Lessons From History, Application of Cognitive Science Principles, and Recommendations for Change. Transfusion Medicine Reviews, 2007, 21, 205-222.	2.0	38
10	Declining hepatitisÂC rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion, 2008, 48, 902-909.	1.6	37
11	Residual risk of HIV, HCV and HBV in Canada. Transfusion and Apheresis Science, 2017, 56, 389-391.	1.0	29
12	Seroprevalence of <scp><i>B</i></scp> <i>abesia microti</i> infection in <scp>C</scp> anadian blood donors. Transfusion, 2016, 56, 237-243.	1.6	27
13	Compliance with timeâ€based deferrals for men who have sex with men. Transfusion, 2019, 59, 916-920.	1.6	27
14	Reassessment of deferrals for tattooing and piercing. Transfusion, 2009, 49, 648-654.	1.6	25
15	Predictive ability of sequential surveys in determining donor loss from increasingly stringent variant Creutzfeldt-Jakob disease deferral policies. Transfusion, 2006, 46, 461-468.	1.6	24
16	International forum on Occult hepatitis B infection and transfusion safety. Vox Sanguinis, 2019, 114, 397-406.	1.5	23
17	HIV residual risk in Canada under a threeâ€month deferral for men who have sex with men. Vox Sanguinis, 2020, 115, 133-139.	1.5	22
18	Research initiatives of blood services worldwide in response to the covidâ€19 pandemic. Vox Sanguinis, 2021. 116. 296-304.	1.5	22

#	Article	IF	CITATIONS
19	Surveillance of Transfusion-Transmissible Infections. Transfusion Medicine Reviews, 2012, 26, 38-57.	2.0	21
20	Impact of a 5â€year deferral from blood donation for men who have sex with men. Transfusion, 2016, 56, 1598-1602.	1.6	21
21	The Canadian donor health assessment questionnaire: can it be improved?. Transfusion, 2006, 46, 2169-2175.	1.6	20
22	Assessment of a travel question to identify donors with risk of Trypanosoma cruzi: operational validity and field testing. Transfusion, 2008, 48, 755-761.	1.6	19
23	Face-to-face interviewing in predonation screening: lack of effect on detected human immunodeficiency virus and hepatitis C virus infections. Transfusion, 2006, 46, 1380-1387.	1.6	18
24	Changing the deferral for men who have sex with men – an improved model to estimate HIV residual risk. Vox Sanguinis, 2019, 114, 666-674.	1.5	17
25	International survey on the impact of parasitic infections: frequency of transmission and current mitigation strategies. Vox Sanguinis, 2019, 114, 17-27.	1.5	15
26	<scp>HIV</scp> incidence and compliance with deferral criteria over three progressively shorter time deferrals for men who have sex with men in Canada. Transfusion, 2022, 62, 125-134.	1.6	14
27	SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada: a cross-sectional study. BMJ Open, 2022, 12, e057846.	1.9	14
28	Prevalence of <i>Babesia</i> in Canadian blood donors: June–October 2018. Transfusion, 2019, 59, 3171-3176.	1.6	13
29	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. PLoS ONE, 2021, 16, e0257743.	2.5	13
30	Malaria blood safety policy in five non-endemic countries: a retrospective comparison through the lens of the ABO risk-based decision-making framework. Blood Transfusion, 2019, 17, 94-102.	0.4	12
31	Twoâ€year followâ€up of donors in a large national study of ferritin testing. Transfusion, 2018, 58, 2868-2873.	1.6	11
32	Changes in minimum hemoglobin and interdonation interval: impact on donor hemoglobin and donation frequency. Transfusion, 2019, 59, 1734-1741.	1.6	10
33	Evaluation of a preâ€exposure prophylaxis (PrEP)/postâ€exposure prophylaxis (PEP) deferral policy among blood donors. Transfusion, 2021, 61, 1684-1689.	1.6	10
34	Impact of informing donors of low ferritin results. Transfusion, 2016, 56, 2193-2198.	1.6	9
35	Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era. Microbiology Spectrum, 2022, 10, e0033922.	3.0	9
36	Staff perspectives on barriers and enablers to implementing alternative source plasma eligibility criteria for gay, bisexual, and other men who have sex with men. Transfusion, 2022, 62, 1571-1582.	1.6	9

#	Article	IF	CITATIONS
37	Resistance of SARSâ€CoV â€2 beta and gamma variants to plasma collected from Canadian blood donors during the spring of 2020. Transfusion, 2021, , .	1.6	8
38	Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays. Microbiology Spectrum, 2022, 10, e0256321.	3.0	8
39	A Prospective Observational Cohort Comparison of SARS-CoV-2 Seroprevalence Between Paramedics and Matched Blood Donors in Canada During the COVID-19 Pandemic. Annals of Emergency Medicine, 2022, 80, 38-45.	0.6	8
40	Behaviour based screening questions and potential donation loss using the "for the assessment of individualised risk―screening criteria: A Canadian perspective. Transfusion Medicine, 2022, 32, 422-427.	1.1	8
41	Impact of a policy to permit the return of donors repeatâ€reactive to the Abbott PRISM antibody to hepatitis B core antigen assay. Transfusion, 2009, 49, 271-277.	1.6	7
42	Human T ell lymphotropic virus: A simulation model to estimate residual risk with universal leucoreduction and testing strategies in Canada. Vox Sanguinis, 2018, 113, 750-759.	1.5	7
43	<scp>HIV</scp> residual risk in Canada for apheresis source plasma donation without deferral for men who have sex with men. Vox Sanguinis, 2022, 117, 201-207.	1.5	7
44	International Forum on Occult hepatitis B infection and transfusion safety. Vox Sanguinis, 2019, 114, e1-e35.	1.5	6
45	An international comparison of antiâ€SARS OVâ€2 assays used for seroprevalence surveys from blood component providers. Vox Sanguinis, 2021, 116, 946-954.	1.5	6
46	The impact of donor ferritin testing on blood availability in Canada. Vox Sanguinis, 2022, 117, 17-26.	1.5	6
47	International survey of strategies to mitigate t <scp>ransfusionâ€ŧransmitted</scp> <i>Trypanosoma cruzi</i> in n <scp>onâ€endemic</scp> countries, 2016–2018. Vox Sanguinis, 2022, 117, 58-63.	1.5	6
48	Risk of transfusionâ€ŧransmitted <i>Babesia microti</i> in Canada. Transfusion, 2021, 61, 2958-2968.	1.6	6
49	Early warning and rapid public health response to prevent COVID-19 outbreaks in long-term care facilities (LTCF) by monitoring SARS-CoV-2 RNA in LTCF site-specific sewage samples and assessment of antibodies response in this population: prospective study protocol. BMJ Open, 2021, 11, e052282.	1.9	6
50	Impact of changes to policy for Mexican risk travel on Canadian blood donor deferrals. Blood Transfusion, 2013, 11, 580-4.	0.4	6
51	Canadian blood suppliers: An expanding role in public health surveillance?. Canada Communicable Disease Report, 2022, 48, 124-130.	1.3	6
52	Evaluation of selective screening of donors for antibody to <scp><i>Trypanosoma cruzi</i></scp> : seroprevalence of donors who answer "no―to risk questions. Transfusion, 2014, 54, 863-869.	1.6	5
53	Assignment of cytomegalovirus infection status in infants awaiting solid organ transplant: Viral detection methods as adjuncts to serology. Pediatric Transplantation, 2018, 22, e13229.	1.0	5
54	Evaluating the Clinical Effect of Female Blood Donors of Child-Bearing Age on Maternal and Neonatal Outcomes: A Cohort Study. Transfusion Medicine Reviews, 2020, 34, 117-123.	2.0	5

#	Article	IF	CITATIONS
55	Current challenges of severe acute respiratory syndrome coronavirus 2 seroprevalence studies among blood donors: A scoping review. Vox Sanguinis, 2022, 117, 476-487.	1.5	5
56	SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History. Microbiology Spectrum, 2022, 10, e0226221.	3.0	5
57	Assessing unintentional creation of bias against men who have sex with men as a function of exposure to blood donor screening questionnaire: A national randomized controlled trial. Transfusion, 2022, 62, 1399-1407.	1.6	5
58	A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021. Microbiology Spectrum, 0, , .	3.0	5
59	Donor iron policy: from research to practice. Transfusion, 2016, 56, 1496-1498.	1.6	4
60	An international comparison of HIV prevalence and incidence in blood donors and general population: a BEST Collaborative study. Vox Sanguinis, 2021, 116, 1084-1093.	1.5	4
61	Babesia microti in a Canadian blood donor and lookback in a red blood cell recipient. Vox Sanguinis, 2021, , .	1.5	4
62	Are donors in Canada compliant with deferral for tattoos and piercing?. Blood Transfusion, 2014, 12, 141-2.	0.4	4
63	Moving from a permanent to a 5 year deferral for donors with cured cancer results in a substantial reduction in deferral rates. ISBT Science Series, 2018, 13, 429-431.	1.1	3
64	The estimated risk of SARS-CoV- 2 infection via cornea transplant in Canada. Cell and Tissue Banking, 2021, 22, 685-695.	1.1	3
65	Transfusionâ€transmitted and communityâ€acquired cytomegalovirus infection in seronegative solid organ transplant recipients receiving seronegative donor organs. American Journal of Transplantation, 2020, 20, 3509-3519.	4.7	3
66	Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273. Microbiology Spectrum, 2022, 10, e0270221.	3.0	3
67	Balancing nonâ€discriminatory donor selection and blood safety in the Netherlands: Evaluation of an individual risk assessment of sexual behavior. Transfusion, 2022, 62, 1241-1250.	1.6	3
68	Changing donor policy for men who have sex with men: it's all about the data. Annals of Blood, 0, 5, 16-16.	0.4	2
69	Transfusion-transmitted malaria: is hope around the corner?. Lancet, The, 2016, 387, 1701-1703.	13.7	1
70	Themed issue – focusing on donor assessment, motivation and vigilance. Vox Sanguinis, 2021, 116, 257-259.	1.5	1
71	Whole blood donor return rates after deferral for tattooing or body piercing—Survey across blood donation services: The <scp>BEST</scp> collaborative study. Vox Sanguinis, 2022, 117, 1085-1089.	1.5	1
72	Is high hemoglobin a hindrance factor for blood donation? A pilot observational study from the coastal region of India. Transfusion Clinique Et Biologique, 2022, 29, 147-152.	0.4	0

#	Article	IF	CITATIONS
73	An uncertain association between influenza season, recent influenza vaccination campaigns, and unconfirmed repeat reactive syphilis serology assay results in Canadian blood donors. Transfusion, 2022, 62, 510-512.	1.6	0